Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor
Titel:
Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor
Auteur:
Verstovsek, Srdan Tam, Constantine S. Wadleigh, Martha Sokol, Lubomir Smith, Catherine C. Bui, Lynne A. Song, Chunyan Clary, Douglas O. Olszynski, Patrycja Cortes, Jorge Kantarjian, Hagop Shah, Neil P.